You are currently viewing COVID-19 online vaccination event postponed due to AstraZeneca pause

COVID-19 online vaccination event postponed due to AstraZeneca pause

You may be aware of the temporary pause in the vaccination programme for AstraZeneca.

This recommendation has been made following a report from the Norwegian Medicines Agency of four new reports of serious blood clotting events in adults after vaccination with Covid-19 Vaccine AstraZeneca. It has not been concluded that there is any link between the COVID-19 Vaccine AstraZeneca and these cases. However, acting on the precautionary principle, and pending receipt of further information, the NIAC has recommended the temporary deferral of the COVID-19 AstraZeneca vaccination programme in Ireland.

We expect further clarifications on Thursday of this week.

Therefore, we are postponing Monday’s online event, until further notice. When this information is available, we will re-schedule as the event will be more informative and useful at that time. Apologies for any inconvenience caused.

We have attempted to address some of your immediate concerns below.

Questions and Answers

Why has the use of AstraZeneca Vaccine been temporarily deferred?

Following a new safety alert received late on Saturday, 13th March (from Norway), and pending receipt of further information from the EMA, as a precaution, the National Immunisation Advisory Committee (NIAC) have recommended a temporary deferral of administration of COVID-19 Vaccine AstraZeneca in Ireland.

Pending further advice, the use of AstraZeneca vaccine will be temporarily deferred for the week commencing Sunday,14th March 2021.

The alert originated from the Norwegian Medicines Agency following four new reports of serious rare clotting, or thromboembolic events, including some complicated by low platelet levels, or thrombocytopenia, in younger adults. These occurred after vaccination with COVID-19 Vaccine AstraZeneca. At this time, no link between these events and the vaccine have been confirmed.

The European Medicines Agency (EMA) is already investigating a number of reports of thromboembolic events from the AstraZeneca Vaccine and a report is expected over the coming days.

EMA information from 12th March was that the number of clotting or thromboembolic events in vaccinated people is no higher than the number seen in the general population. As of 10th March 2021, 30 cases of thromboembolic events had been reported among close to 5 million people vaccinated with COVID-19 Vaccine AstraZeneca in the European Economic Area.

This vaccine along with the others, is a very important tool in our fight against COVID-19 disease.

Does this safety report prove AstraZeneca is not safe ?


Determining whether an outcome is directly caused by a treatment (causation) or occurs coincidentally, is an age-old problem. There are many examples, where two events being linked (association) may have been mistaken for one event causing the other (causation). It is important that when assessing the evidence of a causative effect, (for example, health problems after vaccination) proper investigation is conducted to rule out other reasons. For instance, cheese consumption in the US between 2000 and 2009 correlated with the number of deaths by entanglement of people in their bedsheets. Does cheese consumption cause a higher risk of death by entanglement of people in their bedsheets? Probably not.

Which groups will be affected by this temporary deferral?

Vaccination of people aged 70 and over will not be affected. This group is being vaccinated by their GPs with mRNA vaccines, which are not part of the temporary deferral.

The groups likely to be affected are frontline healthcare workers, and the planned vaccinations for Group 4 – people who have conditions that put them at very high risk if they get COVID-19 which includes transplant recipients and dialysis patients (GFR less than 15).

What should I do if I have an appointment today or in the next few days to receive COVID-19 Vaccine AstraZeneca?

You should not attend your appointment for COVID-19 Vaccine AstraZeneca until you receive further contact from the HSE or your healthcare team about the resumption of the programme.

You should continue to follow all COVID-19 precautions in the meantime.

Any appointments for a first or second dose of Pfizer/BioNTech or Moderna COVID-19 vaccine can still go ahead as they are not included in this safety alert. This includes appointments for people aged 70 and over who are being vaccinated by GPs.

What about my second dose of COVID-19 Vaccine AstraZeneca ?

The recommended interval between the first and second dose of COVID-19 Vaccine AstraZeneca is 12 weeks. There are no appointments scheduled for second doses at the present time. Further information will be provided about second doses as soon as it is available.

What should I do if I have already received COVID-19 Vaccine AstraZeneca?

The events reported are very rare, and we do not know if they are caused by the vaccine. This vaccine is a very important tool in our fight against COVID-19 disease.

We know that side effects of COVID-19 Vaccine AstraZeneca can occur within the first couple of days of the vaccine.

After the AstraZeneca COVID-19 vaccine, more than 1 in 10 people may experience:

· feeling tired

· tenderness, bruising, pain, redness or itching in the arm where they had the vaccine injection

· headache

· muscle pain

· joint pain

· nausea, diarrhoea or vomiting

· fever (temperature of 38 degrees Celsius or above)

More than one in 100 people may have redness or swelling where they had the injection.

It’s common to develop a fever (temperature of 38 degrees Celsius or above) after any vaccination. This usually happens within 2 days (48 hours) of getting the vaccine. It usually goes away within 2 days.

If you feel uncomfortable, take paracetamol or ibuprofen following the instructions on the box or leaflet.

What if I still feel unwell more than 3 days after my vaccine?

People who have received the COVID-19 Vaccine AstraZeneca and feel increasingly unwell for more than three days after vaccination, and/or who notice larger or smaller blue spots in the skin (purpuric, non-blanching rash, skin haemorrhages) should consult a doctor or out-of-hours medical service.

The rare events that have been reported have usually occurred within 14 days of the vaccine. And, it’s important to remember that there is no proven link between these events and the vaccine at this time.

What else should we remember?

COVID-19 is a serious disease which has caused significant disease and death across the world including Ireland. COVID-19 vaccines have been developed and authorised for use after rigorous testing and have a favourable safety profile.

More than 100,000 doses of COVID-19 Vaccine AstraZeneca have been used in Ireland so far, mainly in frontline healthcare workers, and we can already see the significant reduction in cases of COVID-19 disease in this group after the vaccine programme.

What are the next steps?

Further information is expected from the EMA in the next few days, which will include a review of these additional events. This information will be reviewed by NIAC and further advice on the programme will be issued following this. The HSE, NIAC and the Department of Health will continue to keep people updated and share information as it is available.